<u>Claims</u>

1. A pharmaceutical preparation comprising a synergistic combination of abacavir and allowudine and a pharmaceutical carrier therefor.

5

- 2. A preparation according to claim 1 wherein the allowedine is present in an amount of 1-10 mg per unit dose.
- 3. A preparation according to claim 2 wherein the allowedine is present in an amount of 0.5-7.5 mg per unit dose.
 - 4. A preparation according to claim 3 wherein the allowedine is present in an amount of 0.5-5 mg per unit dose.
- 5. A preparation according to claim 1, wherein the abacavir is present in an amount of 200-800 mg per unit dose.
 - 6. A preparation according to claim 5, wherein the abacavir is present in an amount of 300-500 mg per unit dose.

20

25

- 7. A preparation according to claim 1, wherein the allowedine and abacavir are present in a weight ratio corresponding to their respective ED₅₀.
- 8. A preparation according to claim 1, wherein the alovudine and abacavir are present in the ratio 1-10:200-800
- 9. A patient pack comprising allowedine and/or abacavir and an information insert containing directions on the use of both allowedine and abacavir together in combination.

30

10. Use of abacavir and allowedine together for the treatment of multiresistant HIV, wherein the use comprises simultaneous, combined or sequential administration of allowedine and abacavir.

11. Use according to claim 10, wherein the use comprises administration of a preparation as defined in any one of claims 1-8 or the patient pack of claim 9.